H. Lundbeck stock

HLUN.A · Nasdaq Copenhagen · DKK

kr 56.90Change from previous close: −2.23%Absolute change: −kr 1.30

Close · November 16, 2026

Price history

+65.65% over the period

1 year: from kr 34.35 (November 17, 2025) to kr 56.90 (November 16, 2026), +65.65%.

Show chart data

Closing prices adjusted for splits: the last close of each month.

DateClose
November 16, 2026kr 56.90
October 30, 2026kr 50.00
September 30, 2026kr 42.70
August 31, 2026kr 41.80
July 31, 2026kr 36.00
June 30, 2026kr 36.60
May 29, 2026kr 36.80
April 30, 2026kr 35.40
March 31, 2026kr 33.40
February 27, 2026kr 34.80
January 30, 2026kr 36.85
December 30, 2025kr 36.20
November 28, 2025kr 35.00
November 17, 2025kr 34.35

At a glance

  • The company

    Research, develop, manufacture and commercialize pharmaceuticals for psychiatric and neurological disorders

  • Latest results

    Quarter to June 30, 2026 · EPS kr 1.16

TickerLandia's take on H. Lundbeck

Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks

Where the price stands

52-wk lowkr 31.40
52-wk highkr 62.00

−8.23% from the 52-week high

TickerLandia Fingerprint: H. Lundbeck

Compared with similar companies: very strong momentum.

Financials and price compared with 39 companies in the drug manufacturers - specialty & generic industry, worldwide. Momentum and risk compared with 1,160 European stocks.

Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 16, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated

Valuation

H. Lundbeck is pricier than in the past and cheaper than similar companies

On the latest fiscal year's earnings (2025), H. Lundbeck's P/E today is 17.7, above the median of its last 4 fiscal years (11.8; between 10.5 and 12.4 from 2022 to 2025). H. Lundbeck's P/E (trailing 12 months): 14.2, −26% against the median of a group of 11 similar companies (19.4).

P/E compared with its history

Compared with 11 similar companies

H. Lundbeck's metrics compared with similar companies
MetricH. LundbeckPosition in the groupBand
P/E (trailing 12 months)14.2Low
Operating margin24.4%High
ROE15.4%Middle
Debt/equity0.31Middle
Price/book2.04Middle

P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: H. Lundbeck. All multiples and dividends

TickerLandia analysisHow it is calculated

The financials

The business in numbers

Revenue

kr 6.46B

Latest quarter · Q2 2026

Net income

kr 1.15B

Latest quarter · Q2 2026

Quarterly net margin

17.8%

Latest quarter · Q2 2026

Numbers and valuation

Full valuation
Market cap
kr 57.74B
P/E
14.2
EPS
kr 4.09
Volume
40.31K
Daily trading
€523.14K
Dividend yield
2.02%
Last ex-dividend on March 19, 2026

How H. Lundbeck is changing

All results
  • Revenue grew 6.9% a year on average over the last 5 years

  • Operating margin rose from 15.6% to 23.9%

  • Profits turn into cash: free cash flow equal to 130% of net income

Returns

H. Lundbeck returns with dividends

kr 1,000 invested in H. Lundbeck 3 years ago, on November 16, 2023, would be worth kr 2,082 today with dividends reinvested: +108.25% in total, +27.69% per year. On price alone it would be kr 1,904 (+90.43%).

PeriodH. Lundbeckkr 1,000 becomes
1 month+26.30%kr 1,263
6 months+58.06%kr 1,581
Year to date+57.18%kr 1,572
1 year+71.34%kr 1,713
3 years+108.25%kr 2,082

From 1 year up with dividends reinvested, before taxes; under a year price only. Calculate your investment

The chart in detail

H. Lundbeck: technical analysis

H. Lundbeck is in an uptrend: the price is above its 50- and 200-session moving averages, and the 200-session average is rising. The price is 4.5% below its all-time closing high (kr 59.60, November 11, 2026).

Trend
Upward
RSI (14 sessions)
71
Above 70: a strong rise in a short time
vs 200-session average
+47.19%

Active signals

  • RSI above 70: the stock has risen a lot in a short time.

    since October 20, 2026

Support and resistance

Price areas where H. Lundbeck has stopped several times in the last year. They describe the chart; they are not forecasts.

  1. No resistance above: the price is near the highs of the year
  2. Last pricekr 56.90
  3. Supportkr 44.63−21.56%3 touches, last on September 28, 2026
  4. Supportkr 37.44−34.20%4 touches, last on July 3, 2026
  5. Supportkr 36.23−36.33%9 touches, last on July 31, 2026

Volatility and risk

Volatility (60 sessions, annualised)
34.7%
Largest fall in the last year
−20.18%

In session, November 16, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it

The company

H. Lundbeck and its competitors

Patients with psychiatric and neurological disorders in Europe, the United States and other international markets are served by H. Lundbeck A/S, which researches, develops, manufactures and commercializes pharmaceuticals for these conditions, including schizophrenia, bipolar I disorder, depression, migraine, epilepsy, dementia and Parkinson's disease. Its products include Abilify Maintena, Brintellix, Rexulti, Vyepti and Azilect. Its pipeline includes Eptinezumab in phase 3 testing for cluster headache and bexicaserin in phase 3 for developmental and epileptic encephalopathies.

Headquarters
Valby, Denmark
Employees
5,000
H. Lundbeck and its competitors
CompanyMarket capOperating marginP/E (trailing 12 months)6 months
H. LundbeckHLUN.A$8.54B24.4%14.2+58.06%
IpsenIPN$15.16B27.4%26.9+0.60%
Swedish Orphan BiovitrumSOBI$16.42B30.9%25.0+8.39%
Laboratorios Farmaceuticos RoviROVI$3.57B19.5%17.4+18.15%
Siegfried HoldingSFZN$3.67B16.7%18.0−11.22%
AlmirallALM$2.57B13.3%32.4−5.83%

Same industry or related industries, similar size. Compare H. Lundbeck with its competitors · Full profile